The team, made up of investigators from the UK and the US, will receive $25 million address the challenge of cancer cachexia, the debilitating wasting condition responsible for up to 30% of cancer-related deaths.
WASHINGTON , June 16, 2022 /PRNewswire/ — LUNGevity is honored to be the U.S. patient advocacy organization part of the new Cancer Grand Challenges team taking on the challenge of cancer cachexia, a wasting syndrome associated with advanced cancer. . The CANCAN (Cancer Cachexia Action Network) team, made up of researchers from the UK and the US, will receive $25 million to tackle this critical hurdle in cancer research. The Cancer Cachexia Action Network represents the world’s first virtual institute whose mission is to solve cancer cachexia.
“We need new approaches to detect cachexia as early as possible to give patients the best possible outcomes,” said Amy Moore, PhD, Vice President of Global Engagement and Patient Partnerships at the LUNGevity Foundation. “It is an extraordinary honor for LUNGevity to be included as a patient advocacy organization with Cancer Grand Challenges. I am in awe of the passion and genius of the team, and see very clearly that their purpose is to bring the latest scientific discoveries to what has been an unsolvable problem, not only for cancer patients, but for other diseases as well.When scientists work together in this way, patients benefit, and c is what matters most.
The Cancer Grand Challenges CANCAN team, led by Eileen White from the Rutgers Cancer Institute of New Jersey, Marcus Da Silva Goncalves from Weill Cornell Medicine, and Tobie Janowitz from the Cold Spring Harbor Laboratory, will address the challenge of cancer cachexia. Cachexia is a debilitating wasting condition that people often experience in the late stages of their cancer that results in a poor prognosis and poor quality of life. Although cachexia is a major clinical problem, very little is known about it and there is no effective treatment for people who suffer from it. The team hopes to gain a deeper understanding of the causes of cachexia and develop new treatments to intervene, which could transform people’s quality of life and, ultimately, survival.
“Cancer is a global problem that must be solved through global collaboration. This investment in team science encourages diverse thinking about issues like cachexia that have long impeded research progress,” said David Scott, PhD, Director of Cancer Grand Challenges, Cancer Research UK. “Cancer Grand Challenges provides multidisciplinary teams with the time, space and funding to foster innovation and a transformative approach. CANCAN is one of four newly funded teams joining a scientific community addressing unmet clinical needs in cancer research.
About the LUNGevity Foundation
The LUNGevity Foundation is the leading national lung cancer organization focused on improving outcomes for people living with lung cancer through research, education, policy initiatives, and advocacy. to support and engage patients, survivors and caregivers. LUNGevity seeks to have an immediate impact on the quality of life and survival of all people affected by the disease, while promoting health equity by addressing disparities along the continuum of care. LUNGevity works tirelessly to advance research into early detection and more effective treatments, provide information and educational tools to empower patients and their caregivers, promote impactful public policy initiatives, and amplify patient voices through research. and commitment. The organization provides an active community for patients and survivors – and those who help them live better, longer lives.
Comprehensive resources include a medically vetted and patient-centered website, a toll-free helpline, the International Lung Cancer Survivorship Conference, and an easy-to-use clinical trial search tool, among other tools. All of these programs aim to achieve our vision: a world where no one dies from lung cancer. The LUNGevity Foundation is proud to be a four-star Charity Navigator organization.
About Lung Cancer in the United States
- About 1 in 17 Americans will be diagnosed with lung cancer in their lifetime.
- More than 236,000 people in the United States will be diagnosed with lung cancer this year.
- About 60-65% of all new lung cancer diagnoses are in people who have never smoked or are former smokers.
- Lung cancer takes more lives United States than the next two deadliest cancers (colorectal and pancreatic) combined.
- Only about 23% of all people diagnosed with lung cancer in United States will survive 5 years or more, BUT if caught before it spreads, the chances of survival at 5 years improve dramatically.
Please visit LUNGevity.org to learn more.
About the Cancer Grand Challenges
Cancer Grand Challenges is a global funding initiative founded in 2020 by the two largest cancer research funders in the world: Cancer Research UK and the National Cancer Institute* in the United States.
Cancer Grand Challenges supports a global community of diverse, world-class research teams with prizes of £20 million/$25 million to come together, think differently and tackle the toughest challenges in cancer. Cancer Grand Challenges teams are empowered to cross traditional boundaries of geography and discipline.
Learn more: www.cancergrandchallenges.org.
*The National Cancer Institute is part of the National Institutes of Health.
About Cancer Cachexia
Cancer cachexia, also called wasting syndrome or anorexia-cachexia, usually occurs in the later stages of the disease. According to the Cancer Cachexia Society, cachexia is a metabolic disorder that causes unintended weight loss due to a combination of factors, including loss of appetite, muscle wasting, decreased body fat, and increased metabolism. The weight loss attributed to cachexia is caused by the depletion of major tissues, such as skeletal muscle and adipose tissue. The effect of cancer on cells of the immune system and inflammation in the body play a key role in cachexia, but more research is needed to better understand the disease and to cure it. Cancer cachexia is estimated to affect 50% of lung cancer patients.
SOURCE LUNGevity Foundation